Human blood myeloid and plasmacytoid dendritic cells cross activate each other and synergize in inducing NK cell cytotoxicity

References

• Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer 2012; 12:265-77; PMID:22437871; http://dx.doi.org/10.1038/nrc3258
   PubMed Web of Science ®Google Scholar
• Anguille S, Smits EL, Lion E, van Tendeloo VF, Berneman ZN. Clinical use of dendritic cells for cancer therapy. Lancet Oncol 2014; 15:e257-67; PMID:24872109; http://dx.doi.org/10.1016/S1470-2045(13)70585-0
   PubMed Web of Science ®Google Scholar
• Wimmers F, Schreibelt G, Sköld AE, Figdor CG, De Vries IJM. Paradigm shift in dendritic cell-based immunotherapy: from in vitro generated monocyte-derived DCs to naturally circulating DC subsets. Front Immunol 2014; 5:165; PMID:24782868; http://dx.doi.org/10.3389/fimmu.2014.00165
   PubMed Web of Science ®Google Scholar
• Dzionek A, Fuchs A, Schmidt P, Cremer S, Zysk M, Miltenyi S, Buck DW, Schmitz J. BDCA-2, BDCA-3, and BDCA-4: three markers for distinct subsets of dendritic cells in human peripheral blood. J Immunol 2000; 165:6037-46; PMID:11086035; http://dx.doi.org/10.4049/jimmunol.165.11.6037
   PubMed Web of Science ®Google Scholar
• Jarrossay D, Napolitani G, Colonna M, Sallusto F, Lanzavecchia A. Specialization and complementarity in microbial molecule recognition by human myeloid and plasmacytoid dendritic cells. Eur J Immunol 2001; 31:3388-93; PMID:11745357; http://dx.doi.org/10.1002/1521-4141(200111)31:11%3c3388::AID-IMMU3388%3e3.0.CO;2-Q
   PubMed Web of Science ®Google Scholar
• Kadowaki N, Ho S, Antonenko S, Malefyt RW, Kastelein RA, Bazan F, Liu YJ. Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J Exp Med 2001; 194:863-9; PMID:11561001; http://dx.doi.org/10.1084/jem.194.6.863
   PubMed Web of Science ®Google Scholar
• Krug A, Towarowski A, Britsch S, Rothenfusser S, Hornung V, Bals R, Giese T, Engelmann H, Endres S, Krieg AM et al. Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. Eur J Immunol 2001; 31:3026-37; PMID:11592079; http://dx.doi.org/10.1002/1521-4141(2001010)31:10%3c3026::AID-IMMU3026%3e3.0.CO;2-H
   PubMed Web of Science ®Google Scholar
• Nizzoli G, Krietsch J, Weick A, Steinfelder S, Facciotti F, Gruarin P, Bianco A, Steckel B, Moro M, Crosti M et al. Human CD1c+ dendritic cells secrete high levels of IL-12 and potently prime cytotoxic T-cell responses. Blood 2013; 122:932-42; PMID:23794066; http://dx.doi.org/10.1182/blood-2013-04-495424
   PubMed Web of Science ®Google Scholar
• Hsieh CS, Macatonia SE, Tripp CS, Wolf SF, O'Garra A, Murphy KM. Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. Science 1993; 260:547-9; PMID:8097338; http://dx.doi.org/10.1126/science.8097338
   PubMed Web of Science ®Google Scholar
• Pearce EL, Shen H. Generation of CD8 T cell memory is regulated by IL-12. J Immunol 2007; 179:2074-81; PMID:17675465; http://dx.doi.org/10.4049/jimmunol.179.4.2074
   PubMed Web of Science ®Google Scholar
• Swiecki M, Colonna M. The multifaceted biology of plasmacytoid dendritic cells. Nat Rev Immunol 2015; 15:471-85; PMID:26160613; http://dx.doi.org/10.1038/nri3865
   PubMed Web of Science ®Google Scholar
• Rogge L, D'Ambrosio D, Biffi M, Penna G, Minetti LJ, Presky DH, Adorini L, Sinigaglia F. The role of Stat4 in species-specific regulation of Th cell development by type I IFNs. J Immunol 1998; 161:6567-74; PMID:9862683
   PubMed Web of Science ®Google Scholar
• Biron CA, Nguyen KB, Pien GC, Cousens LP, Salazar-Mather TP. Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu Rev Immunol 1999; 17:189-220; PMID:10358757; http://dx.doi.org/10.1146/annurev.immunol.17.1.189
   PubMed Web of Science ®Google Scholar
• Prue RL, Vari F, Radford KJ, Tong H, Hardy MY, D'Rozario R, Waterhouse NJ, Rossetti T, Coleman R, Tracey C et al. A phase I clinical trial of CD1c (BDCA-1)+ dendritic cells pulsed with HLA-A*0201 peptides for immunotherapy of metastatic hormone refractory prostate cancer. J Immunother 2015; 38:71-6; PMID:25658616; http://dx.doi.org/10.1097/CJI.0000000000000063
   PubMed Web of Science ®Google Scholar
• Tel J, Aarntzen EHJG, Baba T, Schreibelt G, Schulte BM, Benitez-Ribas D, Boerman OC, Croockewit S, Oyen WJG, van Rossum M et al. Natural human plasmacytoid dendritic cells induce antigen-specific T-cell responses in melanoma patients. Cancer Res 2013; 73:1063-75.; PMID:23345163; http://dx.doi.org/10.1158/0008-5472.CAN-12-2583
   PubMed Web of Science ®Google Scholar
• Schreibelt G, Bol KF, Westdorp H, Wimmers F, Aarntzen EHJG, Duiveman-de Boer T, van de Rakt MWMM, Scharenborg NM, de Boer AJ, Pots JM et al. Effective clinical responses in metastatic melanoma patients after vaccination with primary myeloid dendritic cells. Clin Cancer Res 2015; 22:2155-66; PMID:26712687; http://dx.doi.org/10.1158/1078-0432.CCR-15-2205
   PubMed Web of Science ®Google Scholar
• Baxevanis CN, Voutsas IF, Tsitsilonis OE, Gritzapis AD, Sotiriadou R, Papamichail M. Tumor-specific CD4+ T lymphocytes from cancer patients are required for optimal induction of cytotoxic T cells against the autologous tumor. J Immunol 2000; 164:3902-12; PMID:10725753; http://dx.doi.org/10.4049/jimmunol.164.7.3902
   PubMed Web of Science ®Google Scholar
• Aarntzen EHJG, De Vries IJM, Lesterhuis WJ, Schuurhuis D, Jacobs JFM, Bol K, Schreibelt G, Mus R, De Wilt JHW, Haanen JBAG et al. Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination. Cancer Res 2013; 73:19-29; PMID:23087058; http://dx.doi.org/10.1158/0008-5472.CAN-12-1127
   PubMed Web of Science ®Google Scholar
• Knutson KL, Disis ML. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol Immunother 2005; 54:721-8; PMID:16010587; http://dx.doi.org/10.1007/s00262-004-0653-2
   PubMed Web of Science ®Google Scholar
• Viguier M, Lemaître F, Verola O, Cho M-S, Gorochov G, Dubertret L, Bachelez H, Kourilsky P, Ferradini L. Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol 2004; 173:1444-53; PMID:15240741; http://dx.doi.org/10.4049/jimmunol.173.2.1444
   PubMed Web of Science ®Google Scholar
• Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer 2012; 12:278-87; PMID:22437872; http://dx.doi.org/10.1038/nrc3236
   PubMed Web of Science ®Google Scholar
• Jego G, Palucka AK, Blanck J-P, Chalouni C, Pascual V, Banchereau J. Plasmacytoid dendritic cells induce plasma cell differentiation through Type I interferon and interleukin 6. Immunity 2003; 19:225-34; PMID:12932356; http://dx.doi.org/10.1016/S1074-7613(03)00208-5
   PubMed Web of Science ®Google Scholar
• Nguyen KB, Salazar-Mather TP, Dalod MY, Van Deusen JB, Wei X, Liew FY, Caligiuri MA, Durbin JE, Biron CA. Coordinated and distinct roles for IFN-α β, IL-12, and IL-15 regulation of NK cell responses to viral infection. J Immunol 2002; 169:4279-87; PMID:12370359; http://dx.doi.org/10.4049/jimmunol.169.8.4279
   PubMed Web of Science ®Google Scholar
• Krug A, Rothenfusser S, Hornung V, Jahrsdörfer B, Blackwell S, Ballas ZK, Endres S, Krieg AM, Hartmann G. Identification of CpG oligonucleotide sequences with high induction of IFN-α/β in plasmacytoid dendritic cells. Eur J Immunol 2001; 31:2154-63; PMID:11449369; http://dx.doi.org/10.1002/1521-4141(200107)31:7%3c2154::AID-IMMU2154%3e3.0.CO;2-U
   PubMed Web of Science ®Google Scholar
• Bakdash G, Schreurs I, Schreibelt G, Tel J. Crosstalk between dendritic cell subsets and implications for dendritic cell-based anticancer immunotherapy. Expert Rev Clin Immunol 2014; 10:915-26; PMID:24758519; http://dx.doi.org/10.1586/1744666X.2014.912561
   PubMed Web of Science ®Google Scholar
• Mathan TSMM, Figdor CG, Buschow SI. Human plasmacytoid dendritic cells: From molecules to intercellular communication network. Front Immunol 2013; 4:372; PMID:24282405; http://dx.doi.org/10.3389/fimmu.2013.00372
   PubMed Web of Science ®Google Scholar
• Lou Y, Liu C, Kim GJ, Liu YJ, Hwu P, Wang G. Plasmacytoid dendritic cells synergize with myeloid dendritic cells in the induction of antigen-specific antitumor immune responses. J Immunol 2007; 178:1534-41; PMID:17237402; http://dx.doi.org/10.4049/jimmunol.178.3.1534
   PubMed Web of Science ®Google Scholar
• Fonteneau JF, Larsson M, Beignon AS, McKenna K, Dasilva I, Amara A, Liu YJ, Lifson JD, Littman DR, Bhardwaj N. Human immunodeficiency virus type 1 activates plasmacytoid dendritic cells and concomitantly induces the bystander maturation of myeloid dendritic cells. J Virol 2004; 78:5223-32; PMID:15113904; http://dx.doi.org/10.1128/JVI.78.10.5223-5232.2004
   PubMed Web of Science ®Google Scholar
• Pérez-Cabezas B, Naranjo-Gómez M, Ruiz-Riol M, Bastos-Amador P, Fernández MA, Carmona F, Nuñez F, Pujol-Borrell R, Borràs FE. TLR-activated conventional DCs promote γ-secretase-mediated conditioning of plasmacytoid DCs. J Leukoc Biol 2012; 92:133-43; http://dx.doi.org/10.1189/jlb.0911452
   PubMed Web of Science ®Google Scholar
• Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne MC et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000; 192:1027-34; PMID:11015443; http://dx.doi.org/10.1084/jem.192.7.1027
   PubMed Web of Science ®Google Scholar
• Qin Z, Richter G, Schüler T, Ibe S, Cao X, Blankenstein T. B cells inhibit induction of T cell-dependent tumor immunity. Nat Med 1998; 4:627-30; PMID:9585241; http://dx.doi.org/10.1038/nm0598-627
   PubMed Web of Science ®Google Scholar
• Shah S, Divekar AA, Hilchey SP, Cho H-M, Newman CL, Shin SU, Nechustan H, Challita-Eid PM, Segal BM, Yi KH et al. Increased rejection of primary tumors in mice lacking B cells: inhibition of anti-tumor CTL and TH1 cytokine responses by B cells. Int J cancer 2005; 117:574-86; PMID:15912532; http://dx.doi.org/10.1002/ijc.21177
   PubMed Web of Science ®Google Scholar
• de Visser KE, Korets LV. Coussens LM. De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell 2005; 7:411-23; PMID:15894262; http://dx.doi.org/10.1016/j.ccr.2005.04.014
   PubMed Web of Science ®Google Scholar
• DiLillo DJ, Yanaba K, Tedder TF. B cells are required for optimal CD4+ and CD8+ T cell tumor immunity: therapeutic B cell depletion enhances B16 melanoma growth in mice. J Immunol 2010; 184:4006-16; PMID:20194720; http://dx.doi.org/10.4049/jimmunol.0903009
   PubMed Web of Science ®Google Scholar
• Li Q, Lao X, Pan Q, Ning N, Yet J, Xu Y, Li S, Chang AE. Adoptive transfer of tumor reactive B cells confers host T-cell immunity and tumor regression. Clin Cancer Res 2011; 17:4987-95; PMID:21690573; http://dx.doi.org/10.1158/1078-0432.CCR-11-0207
   PubMed Web of Science ®Google Scholar
• Sorrentino R, Morello S, Forte G, Montinaro A, De Vita G, Luciano A, Palma G, Arra C, Maiolino P, Adcock IM et al. B cells contribute to the antitumor activity of CpG-oligodeoxynucleotide in a mouse model of metastatic lung carcinoma. Am J Respir Crit Care Med 2011; 183:1369-79; PMID:21278302; http://dx.doi.org/10.1164/rccm.201010-1738OC
   PubMed Web of Science ®Google Scholar
• Wennhold K, Weber TM, Thelen M, Garcia-Marquez M, Chakupurakal G, Klein-Gonzalez N, Fiedler A, Schlösser HA, Fischer R, Theurich S et al. CD40-activated B cells induce anti-tumor immunity in vivo. Oncotarget 2016; PMID:26934557; http://dx.doi.org/10.18632/oncotarget.7720
   PubMed Web of Science ®Google Scholar
• Carmi Y, Spitzer MH, Linde IL, Burt BM, Prestwood TR, Perlman N, Davidson MG, Kenkel JA, Segal E, Pusapati G V et al. Allogeneic IgG combined with dendritic cell stimuli induce antitumour T-cell immunity. Nature 2015; 521:99-104; PMID:25924063; http://dx.doi.org/10.1038/nature14424
   PubMed Web of Science ®Google Scholar
• van Beek JJP, Wimmers F, Hato SV, de Vries IJM, Sköld AE. Dendritic cell cross talk with innate and innate-like effector cells in antitumor immunity: implications for DC vaccination. Crit Rev Immunol 2014; 34:517-36; PMID:25597314; http://dx.doi.org/10.1615/CritRevImmunol.2014012204
   PubMed Web of Science ®Google Scholar
• Gerosa F, Gobbi A, Zorzi P, Burg S, Briere F, Carra G, Trinchieri G. The reciprocal interaction of NK cells with plasmacytoid or myeloid dendritic cells profoundly affects innate resistance functions. J Immunol 2005; 174:727-34; PMID:15634892; http://dx.doi.org/10.4049/jimmunol.174.2.727
   PubMed Web of Science ®Google Scholar
• Sköld AE, Hasan M, Vargas L, Saidi H, Bosquet N, Le Grand R, Smith CIE, Spetz AL. Single-stranded DNA oligonucleotides inhibit TLR3-mediated responses in human monocyte-derived dendritic cells and in vivo in cynomolgus macaques. Blood 2012; 120:768-77; PMID:22700721; http://dx.doi.org/10.1182/blood-2011-12-397778
   PubMed Web of Science ®Google Scholar
• Kreutz M, Bakdash G, Dolen Y, Sköld AE, van Hout-Kuijer MA, de Vries IJM, Figdor CG. Type I IFN-mediated synergistic activation of mouse and human DC subsets by TLR agonists. Eur J Immunol 2015; 45:2798-809; PMID:26255864; http://dx.doi.org/10.1002/eji.201545583
   PubMed Web of Science ®Google Scholar
• Sköld AE, van Beek JJP, Sittig SP, Bakdash G, Tel J, Schreibelt G, de Vries IJM. Protamine-stabilized RNA as an ex vivo stimulant of primary human dendritic cell subsets. Cancer Immunol Immunother 2015; 64:1461-73; PMID:26275446; http://dx.doi.org/10.1007/s00262-015-1746-9
   PubMed Web of Science ®Google Scholar
• Lion E, Anguille S, Berneman ZN, Smits ELJM, Van Tendeloo VFI. Poly(I:C) enhances the susceptibility of leukemic cells to NK cell cytotoxicity and phagocytosis by DC. PLoS One 2011; 6:e20952; PMID:21698118; http://dx.doi.org/10.1371/journal.pone.0020952
   PubMed Web of Science ®Google Scholar